Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Combioxin SA has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner within 1 distinct art unit. RICCI, CRAIG D is the busiest examiner with 1 pending action. This single action represents the company's entire current pending prosecution activity. For a practitioner, this means the prosecution strategy is entirely focused on a single examiner's requirements.
The presence of 1 distinct art unit indicates a specific technical niche for the company's current biotechnology filing. Because there is only 1 distinct examiner involved, the legal team can focus exclusively on the preferences and past actions of RICCI, CRAIG D. There is no complexity arising from multiple art units or varying examiner styles. This 1 pending office action represents a streamlined prosecution path where the outcome is determined by a single examination process. The data shows a highly concentrated intellectual property focus, with no other active matters currently pending in the biotechnology and pharmaceutical sector for this company.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759232 | Treatment of Pneumonia | RICCI, CRAIG D | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18759232 | Treatment of Pneumonia | RICCI, CRAIG D | 1611 | DP | Final Rejection | 10d overdue | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCombioxin SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Craig D Ricci has the most, with 1 of Combioxin SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
